JP2009510084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510084A5 JP2009510084A5 JP2008533586A JP2008533586A JP2009510084A5 JP 2009510084 A5 JP2009510084 A5 JP 2009510084A5 JP 2008533586 A JP2008533586 A JP 2008533586A JP 2008533586 A JP2008533586 A JP 2008533586A JP 2009510084 A5 JP2009510084 A5 JP 2009510084A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- disease
- estriol
- drugs
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 18
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 24
- 229940079593 drug Drugs 0.000 claims 17
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims 10
- 229960001348 estriol Drugs 0.000 claims 10
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 3
- 229940123177 Estrogen receptor beta agonist Drugs 0.000 claims 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229960005309 estradiol Drugs 0.000 claims 3
- 125000000251 estriol group Chemical group 0.000 claims 3
- 229960003399 estrone Drugs 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 229930182833 estradiol Natural products 0.000 claims 2
- 230000001990 hyperexcitatory effect Effects 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 239000002148 ERα-agonist Substances 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- VGHIBOFCBWMZNZ-ZXXIGWHRSA-N NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 VGHIBOFCBWMZNZ-ZXXIGWHRSA-N 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000005899 aromatization reaction Methods 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 229960003836 estriol succinate Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 229940053934 norethindrone Drugs 0.000 claims 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72097205P | 2005-09-26 | 2005-09-26 | |
| US83352706P | 2006-07-26 | 2006-07-26 | |
| PCT/US2006/037752 WO2007038636A2 (en) | 2005-09-26 | 2006-09-26 | Estriol therapy for autoimmune and neurodegenerataive diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510084A JP2009510084A (ja) | 2009-03-12 |
| JP2009510084A5 true JP2009510084A5 (https=) | 2011-01-27 |
Family
ID=37900442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533586A Pending JP2009510084A (ja) | 2005-09-26 | 2006-09-26 | 自己免疫及び神経変性疾患及び障害のためのエストリオール療法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (3) | EP2698167A3 (https=) |
| JP (1) | JP2009510084A (https=) |
| AU (1) | AU2006294662A1 (https=) |
| CA (1) | CA2623839C (https=) |
| WO (1) | WO2007038636A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| US20120328566A9 (en) * | 2001-04-25 | 2012-12-27 | Rhonda R Voskuhl | Estrogen receptor ligand treatment for neurodegenerative diseases |
| US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| US8658627B2 (en) | 2001-04-25 | 2014-02-25 | The Regents Of The University Of California | Pregnancy hormone combination for treatment of autoimmune diseases |
| CA2623905A1 (en) * | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerative diseases and disorders |
| US20100239528A1 (en) * | 2007-07-20 | 2010-09-23 | Stem Cell Therapeutics Corp. | Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta |
| JP5476587B2 (ja) | 2007-10-26 | 2014-04-23 | アカディア ファーマシューティカルズ，インコーポレーテッド | エストロゲン受容体に対して活性を有する縮合化合物 |
| HUP0800414A2 (en) * | 2008-07-04 | 2010-10-28 | Pecsi Tudomanyegyetem | Pharmaceutical combination |
| MX2013010749A (es) | 2011-03-22 | 2013-10-17 | Population Council Inc | Regeneracion de mielina con androgenos. |
| US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
| EP2653163A1 (en) * | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| EP3137087B1 (en) | 2014-04-28 | 2023-09-06 | The Regents of the University of California | Estrogen combination for treatment of multiple sclerosis |
| ES2959603T3 (es) | 2014-04-28 | 2024-02-27 | Univ California | Envase farmacéutico para terapia con estriol para el tratamiento de la esclerosis múltiple |
| JP6213939B2 (ja) * | 2014-06-27 | 2017-10-18 | 国立大学法人名古屋大学 | 標本作製用包埋剤、硬化性基材非浸透標本の作製方法、硬化性基材浸透標本の作製方法、硬化性基材非浸透標本、凍結包埋剤の薄切性改善剤、及び凍結包埋剤 |
| EP3189026B1 (en) * | 2014-09-02 | 2020-07-22 | The Regents of The University of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2016036719A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen therapy for brain gray matter atrophy and associated disability |
| ES2957543T3 (es) | 2014-09-29 | 2024-01-22 | Univ California | Composiciones y métodos para mantener la función cognitiva |
| WO2016160832A1 (en) | 2015-03-30 | 2016-10-06 | The Regents Of The University Of California | Methods of monitoring estriol therapy |
| CN110177572A (zh) * | 2016-09-12 | 2019-08-27 | 史蒂文·霍夫曼 | 用于治疗痴呆的组合物 |
| CN110337265B (zh) * | 2016-11-15 | 2023-02-21 | 加利福尼亚大学董事会 | 用于改善外周神经功能的方法和装置 |
| CA3098602A1 (en) | 2018-05-02 | 2019-11-07 | Pantarhei Oncology B.V. | Treatment of advanced estrogen receptor positive breast cancer |
| TW202124418A (zh) * | 2019-12-20 | 2021-07-01 | 比利時商埃斯特拉有限責任公司 | 壞死性凋亡調節劑、篩選方法及醫藥組成物 |
| CN113243332B (zh) * | 2020-02-07 | 2023-07-28 | 上海市东方医院（同济大学附属东方医院） | 一种广泛脑区神经元树突发育障碍动物模型的制备与应用 |
| WO2022173871A1 (en) | 2021-02-09 | 2022-08-18 | The Regents Of The University Of California | Methods and apparatuses for treating stroke using low-frequency stimulation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| SE9502921D0 (sv) | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| US6734211B1 (en) * | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
| AR027878A1 (es) * | 1999-11-05 | 2003-04-16 | Wyeth Corp | Metodos para identificar y utilizar compuestos inhibidores de amiloides |
| US6265147B1 (en) * | 1999-12-01 | 2001-07-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method of screening for neuroprotective agents |
| WO2002069976A2 (en) * | 2001-03-02 | 2002-09-12 | Stem Cell Therapeutics Inc. | Use of ovarian hormone for increasing neural stem cell number |
| US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| US20050209208A1 (en) * | 2001-04-25 | 2005-09-22 | The Regents Of The University Of California | Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders |
| JP4801868B2 (ja) * | 2002-02-25 | 2011-10-26 | 晃史 山口 | 全身性エリテマトーデス発病抑制薬 |
| EP1358881A1 (en) * | 2002-04-30 | 2003-11-05 | Schering Aktiengesellschaft | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
| CA2623905A1 (en) * | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerative diseases and disorders |
-
2006
- 2006-09-26 EP EP13005320.0A patent/EP2698167A3/en not_active Withdrawn
- 2006-09-26 EP EP16000349.7A patent/EP3045177A1/en not_active Withdrawn
- 2006-09-26 EP EP06815626A patent/EP1929291A4/en not_active Ceased
- 2006-09-26 JP JP2008533586A patent/JP2009510084A/ja active Pending
- 2006-09-26 CA CA2623839A patent/CA2623839C/en not_active Expired - Fee Related
- 2006-09-26 WO PCT/US2006/037752 patent/WO2007038636A2/en not_active Ceased
- 2006-09-26 AU AU2006294662A patent/AU2006294662A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510084A5 (https=) | ||
| US6936599B2 (en) | Estriol therapy for multiple sclerosis and other autoimmune diseases | |
| Cholerton et al. | Estrogen and Alzheimer’s disease: the story so far | |
| US20210137943A1 (en) | Estrogen combination for treatment of multiple sclerosis | |
| EP3206682B1 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| US20140127154A1 (en) | Pregnancy hormone combination for treatment of autoimmune diseases | |
| US20050209208A1 (en) | Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders | |
| AU2006235257A1 (en) | Methods for treating anxiety related disorders | |
| Huber et al. | Treating acne with oral contraceptives: use of lower doses | |
| CN108289958A (zh) | 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱 | |
| AU2003228783C1 (en) | Methods for increasing the therapeutic response to electroconvulsive therapy (''ECT'') | |
| Yoon et al. | Hormone replacement therapy in postmenopausal women with Alzheimer’s disease: a randomized, prospective study | |
| JP2003505336A5 (https=) | ||
| US20120225853A1 (en) | Hormone replacement therapy and depression | |
| EP1432379B1 (en) | Methods for inhibiting cognitive deterioration in adults with down's syndrome | |
| WO2016064997A1 (en) | Compositions and methods for treating fatigue and depression | |
| Parsa et al. | Psychiatric manifestations of olivo-ponto-cerebellar atrophy and treatment with clozapine | |
| Yasuda | Reversible istradefylline-induced pleurothotonus in a patient with Parkinson's disease: A case report and literature review | |
| Tuazon et al. | Beyond contraception and hormone replacement therapy: Advancing Nestorone to a neuroprotective drug in the clinic | |
| Lynn | Fulvestrant (‘Faslodex’)—a new hormonal treatment for advanced breast cancer | |
| South Wales Antidepressant Drug Trial Group | A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness | |
| JP2014508809A (ja) | アンドロゲンを用いたミエリン再生 | |
| Ibrahim et al. | Role of Estrogen in The Treatment of Multiple Sclerosis; Novel Insights Regarding Its Mechanism of Action | |
| Tuazon et al. | Reprint of: Beyond contraception and hormone replacement therapy: Advancing Nestorone to a neuroprotective drug in the clinic | |
| Yal | A case report of arachnoid cyst and bipolar disorder |